IGC Pharma, Inc.
IGC · XNYSCIK 1326205fmd_1DF5XKQNRZ8PCVMT6PXT7G367FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
Latest annual · FY2025
Millions- Total revenues
- 1
- Gross profit
- 1
- Operating income
- (7)
- Net income
- (7)
- Free cash flow
- (5)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (2)
- Net income
- (2)
- Free cash flow
- (1)
Daily close · IGCIEX trades only
Oct 24, 2025 to Nov 11, 2026 · 250 sessions0.20 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +47.4%
- Revenue, 5 yearsFY2020 to FY2025
- -20.8%
- Net income, 5 yearsFY2020 to FY2025
- n/m
IGC Pharma, Inc. (IGC) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.3 million | $1.3 million | -5.5% | 10-K 2025-06-27 · proof |
| Gross profit | $619,000 | $733,000 | -15.6% | 10-K 2025-06-27 · proof |
| Operating income | -$7.4 million | -$9.8 million | 10-K 2025-06-27 · proof | |
| Net income | -$7.1 million | -$13 million | 10-K 2025-06-27 · proof | |
| Cash from operating activities | -$4.8 million | -$5.2 million | 10-K 2025-06-27 · proof | |
| Free cash flow | -$4.9 million | -$5.3 million | 10-K 2025-06-27 · proof | |
| Total assets | $9.7 million | $9.1 million | +7% | 10-KT 2026-03-18 · proof |
| Total liabilities | $2.3 million | $2.8 million | -18.8% | 10-KT 2026-03-18 · proof |
| Cash and cash equivalents | $900,000 | $470,000 | +91.5% | 10-KT 2026-03-18 · proof |
| Total debt | $134,000 | $137,000 | -2.2% | 10-KT 2026-03-18 · proof |
- What was IGC Pharma, Inc. (IGC)'s revenue in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported revenue of $1.3 million for fiscal 2025 (the year ended Mar 31, 2025), against $1.3 million the year before (-5.5%). Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What was IGC Pharma, Inc. (IGC)'s gross profit in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported gross profit of $619,000 for fiscal 2025 (the year ended Mar 31, 2025), against $733,000 the year before (-15.6%). Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What was IGC Pharma, Inc. (IGC)'s operating income in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported operating income of -$7.4 million for fiscal 2025 (the year ended Mar 31, 2025), against -$9.8 million the year before. Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What was IGC Pharma, Inc. (IGC)'s net income in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported net income of -$7.1 million for fiscal 2025 (the year ended Mar 31, 2025), against -$13 million the year before. Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What was IGC Pharma, Inc. (IGC)'s cash from operating activities in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported cash from operating activities of -$4.8 million for fiscal 2025 (the year ended Mar 31, 2025), against -$5.2 million the year before. Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What was IGC Pharma, Inc. (IGC)'s free cash flow in fiscal 2025?
- IGC Pharma, Inc. (IGC) reported free cash flow of -$4.9 million for fiscal 2025 (the year ended Mar 31, 2025), against -$5.3 million the year before. Source: the 10-K filed with the SEC on Jun 27, 2025. SEC
- What are IGC Pharma, Inc. (IGC)'s total assets?
- As of Dec 31, 2025, IGC Pharma, Inc. (IGC) reported total assets of $9.7 million, against $9.1 million a year earlier (+7%). Source: the 10-KT filed with the SEC on Mar 18, 2026. SEC
- What are IGC Pharma, Inc. (IGC)'s total liabilities?
- As of Dec 31, 2025, IGC Pharma, Inc. (IGC) reported total liabilities of $2.3 million, against $2.8 million a year earlier (-18.8%). Source: the 10-KT filed with the SEC on Mar 18, 2026. SEC
- What are IGC Pharma, Inc. (IGC)'s cash and cash equivalents?
- As of Dec 31, 2025, IGC Pharma, Inc. (IGC) reported cash and cash equivalents of $900,000, against $470,000 a year earlier (+91.5%). Source: the 10-KT filed with the SEC on Mar 18, 2026. SEC
- What is IGC Pharma, Inc. (IGC)'s total debt?
- As of Dec 31, 2025, IGC Pharma, Inc. (IGC) reported total debt of $134,000, against $137,000 a year earlier (-2.2%). Source: the 10-KT filed with the SEC on Mar 18, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IGC&period_type=annual&limit=5"Information only, not investment advice.